1. Home
  2. DTCX vs RANI Comparison

DTCX vs RANI Comparison

Compare DTCX & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Datacentrex Inc. Common Stock

DTCX

Datacentrex Inc. Common Stock

BUY

Current Price

$1.31

Market Cap

71.9M

Sector

Technology

ML Signal

BUY

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

BUY

Current Price

$0.61

Market Cap

84.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
DTCX
RANI
Founded
N/A
2012
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.9M
84.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DTCX
RANI
Price
$1.31
$0.61
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $7.20
AVG Volume (30 Days)
174.6K
★ 527.3K
Earning Date
11-22-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
8.00
★ 57.14
EPS
N/A
★ N/A
Revenue
$2,446.00
★ $1,633,000.00
Revenue This Year
N/A
$283.19
Revenue Next Year
N/A
$5.99
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 58.85
52 Week Low
$1.13
$0.57
52 Week High
$3.80
$2.63

Technical Indicators

Market Signals
Indicator
DTCX
RANI
Relative Strength Index (RSI) 31.23 31.61
Support Level N/A N/A
Resistance Level $2.26 $0.85
Average True Range (ATR) 0.16 0.05
MACD -0.03 -0.02
Stochastic Oscillator 22.09 12.79

Price Performance

Historical Comparison
DTCX
RANI

About DTCX Datacentrex Inc. Common Stock

Datacentrex Inc is a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses. Its current operating platform is centered on owned and operated Scrypt-based proof-of-work compute deployed through third-party colocation facilities. Datacentrex monetizes this compute through hashrate marketplace mechanisms and manages a treasury of digital assets and cash in a manner intended to preserve capital and support opportunistic, accretive deployment. The company's operations are principally operated remotely at various data centers throughout the United States.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: